{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-084096","form_type":"8-K","ticker":"SNSE","cik":"0001829802","company_name":"Sensei Biotherapeutics, Inc.","filed_at":"2024-04-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.491414+00:00","generated_at":"2026-06-04T03:51:22.102693+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Sensei Biotherapeutics CFO Erin Colgan resigns effective April 10, 2024","bullets":["Erin Colgan resigns as CFO and all positions, effective April 10, 2024.","Resignation is voluntary and not due to any disagreement with the company.","No successor has been announced; transition details are not provided."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-084096","json":"https://secwatch.observer/filing/0001193125-24-084096.json","markdown":"https://secwatch.observer/filing/0001193125-24-084096.md","text":"https://secwatch.observer/filing/0001193125-24-084096.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1829802/000119312524084096/0001193125-24-084096-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1829802/000119312524084096/d821191d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T03:51:22.102693+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0b89053139","claim":"Erin Colgan resigned as Chief Financial Officer at Sensei Biotherapeutics, Inc..","evidence_excerpt":"On March 27, 2024, Erin Colgan notified Sensei Biotherapeutics, Inc. (the “Company”) of her resignation from all positions with the Company, including as Chief Financial Officer. Ms. Colgan’s resignation is voluntary and will be effective April 10, 2024, and was not related to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1829802/000119312524084096/0001193125-24-084096-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}